GENE AI Analysis Overview
Keys for Bullish View
- Value≥4
- Dividend≥2
Analysis Conclusion
With insufficient quarterly financial data released by the company, we're unable to provide a rating.
GENE Current Performance
8.52%
Genetic technologies limited
1.19%
Avg of Sector
1.11%
S&P500
Top 10 High Relevance to GENE
| Symbol | Company Name | Value | Trend | Swing Trading | Whale Interest | Dividend | Add to Watchlist |
|---|---|---|---|---|---|---|---|
BGXX | Bright green corp | - | 2 | 4 | - | 1 | |
DNTH | Dianthus therapeutics inc | 2 | 4 | 3 | 3 | 1 | |
HLVX | Hillevax inc | - | 2 | 2 | 3 | 1 | |
TRAW | Traws pharma inc | 3 | 1 | 4 | 1 | 1 | |
PSNL | Personalis inc | 3 | 3 | 2 | 2 | 1 |
- BGXX Bright green corpValue -Trend 2Swing Trading 4Whale Interest -Dividend 1See more
GENE Profile
Genetic Technologies Limited is an Australia-based diversified molecular diagnostics company. The Company is engaged in providing genomics-based tests on health, wellness and serious disease through its geneType and EasyDNA brands. The Company offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The Company has a proprietary risk stratification platform that integrates clinical and genetic risk to deliver outcomes to physicians and individuals. The Company operates through three segments: EasyDNA, AffinityDNA, and GeneType / Corporate. EasyDNA segment relates to EasyDNA branded test sales and expenses. AffinityDNA segment relates to AffinityDNA branded test sales and expenses. GeneType / Corporate segment relates to geneType branded test sales and expenses, including corporate charges. The GeneType test is for breast cancer, colorectal cancer, ovarian cancer, prostate cancer, coronary artery disease and mor